A citation-based method for searching scientific literature

A Haouala, B Zanolari, B Rochat, M Montemurro, K Zaman, M A Duchosal, H B Ris, S Leyvraz, N Widmer, L A Decosterd. J Chromatogr B Analyt Technol Biomed Life Sci 2009
Times Cited: 139







List of co-cited articles
555 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS.
Stéphane Bouchet, Emmanuelle Chauzit, Dominique Ducint, Nadège Castaing, Mireille Canal-Raffin, Nicholas Moore, Karine Titier, Mathieu Molimard. Clin Chim Acta 2011
119
38

Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma.
Lutz Götze, Axel Hegele, Stephan Klaus Metzelder, Harald Renz, Wolfgang Andreas Nockher. Clin Chim Acta 2012
67
43

An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry.
L Couchman, M Birch, R Ireland, A Corrigan, S Wickramasinghe, D Josephs, J Spicer, R J Flanagan. Anal Bioanal Chem 2012
53
45

Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Nicolas Widmer, Christophe Bardin, Etienne Chatelut, Angelo Paci, Jos Beijnen, Dominique Levêque, Gareth Veal, Alain Astier. Eur J Cancer 2014
197
24

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.
Stephane Picard, Karine Titier, Gabriel Etienne, Emmanuelle Teilhet, Dominique Ducint, Marie-Agnes Bernard, Regis Lassalle, Gerald Marit, Josy Reiffers, Bernard Begaud,[...]. Blood 2007
451
23


New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.
Silvia De Francia, Antonio D'Avolio, Francesca De Martino, Elisa Pirro, Lorena Baietto, Marco Siccardi, Marco Simiele, Silvia Racca, Giuseppe Saglio, Francesco Di Carlo,[...]. J Chromatogr B Analyt Technol Biomed Life Sci 2009
72
30

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.
Richard A Larson, Brian J Druker, Francois Guilhot, Stephen G O'Brien, Gilles J Riviere, Tillmann Krahnke, Insa Gathmann, Yanfeng Wang. Blood 2008
463
20


Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry.
R Honeywell, K Yarzadah, E Giovannetti, N Losekoot, E F Smit, M Walraven, J S W Lind, C Tibaldi, H M Verheul, G J Peters. J Chromatogr B Analyt Technol Biomed Life Sci 2010
66
25

Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
Huixin Yu, Neeltje Steeghs, Cynthia M Nijenhuis, Jan H M Schellens, Jos H Beijnen, Alwin D R Huitema. Clin Pharmacokinet 2014
155
16

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.
N Widmer, L A Decosterd, S Leyvraz, M A Duchosal, A Rosselet, M Debiec-Rychter, C Csajka, J Biollaz, T Buclin. Br J Cancer 2008
92
16

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
George D Demetri, Yanfeng Wang, Elisabeth Wehrle, Amy Racine, Zariana Nikolova, Charles D Blanke, Heikki Joensuu, Margaret von Mehren. J Clin Oncol 2009
271
14

A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.
Nielka P van Erp, Djoeke de Wit, Henk-Jan Guchelaar, Hans Gelderblom, Trees J Hessing, Jan den Hartigh. J Chromatogr B Analyt Technol Biomed Life Sci 2013
57
24

Clinical pharmacokinetics of tyrosine kinase inhibitors.
Nielka P van Erp, Hans Gelderblom, Henk-Jan Guchelaar. Cancer Treat Rev 2009
290
13

Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Patton Minkin, Ming Zhao, Zhaoyuan Chen, Jan Ouwerkerk, Hans Gelderblom, Sharyn D Baker. J Chromatogr B Analyt Technol Biomed Life Sci 2008
47
27

Moving towards dose individualization of tyrosine kinase inhibitors.
Heinz-Josef Klümpen, Caroline F Samer, Ron H J Mathijssen, Jan H M Schellens, Howard Gurney. Cancer Treat Rev 2011
83
14

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
Brett E Houk, Carlo L Bello, Bill Poland, Lee S Rosen, George D Demetri, Robert J Motzer. Cancer Chemother Pharmacol 2010
364
12


Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
Sandrine Faivre, Catherine Delbaldo, Karina Vera, Caroline Robert, Stéphanie Lozahic, Nathalie Lassau, Carlo Bello, Samuel Deprimo, Nicoletta Brega, Giorgio Massimini,[...]. J Clin Oncol 2006
945
11

Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
N Widmer, L A Decosterd, C Csajka, S Leyvraz, M A Duchosal, A Rosselet, B Rochat, C B Eap, H Henry, J Biollaz,[...]. Br J Clin Pharmacol 2006
124
11



Evidence for therapeutic drug monitoring of targeted anticancer therapies.
Bo Gao, Shang Yeap, Arthur Clements, Bavanthi Balakrishnar, Mark Wong, Howard Gurney. J Clin Oncol 2012
142
11

Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS).
Feng Bai, Burgess B Freeman, Charles H Fraga, Maryam Fouladi, Clinton F Stewart. J Chromatogr B Analyt Technol Biomed Life Sci 2006
40
25


Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry.
Eva Kralj, Jurij Trontelj, Tadej Pajič, Albin Kristl. J Chromatogr B Analyt Technol Biomed Life Sci 2012
45
22


Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
Bin Peng, Michael Hayes, Debra Resta, Amy Racine-Poon, Brian J Druker, Moshe Talpaz, Charles L Sawyers, Marianne Rosamilia, John Ford, Peter Lloyd,[...]. J Clin Oncol 2004
368
9

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
David Marin, Alexandra Bazeos, Francois-Xavier Mahon, Lina Eliasson, Dragana Milojkovic, Marco Bua, Jane F Apperley, Richard Szydlo, Ritti Desai, Kasia Kozlowski,[...]. J Clin Oncol 2010
648
9

Clinical pharmacokinetics of imatinib.
Bin Peng, Peter Lloyd, Horst Schran. Clin Pharmacokinet 2005
426
9

A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients.
Elisa Pirro, Silvia De Francia, Francesca De Martino, Carmen Fava, Stefano Ulisciani, Giovanna Rege Cambrin, Silvia Racca, Giuseppe Saglio, Francesco Di Carlo. J Chromatogr Sci 2011
27
33

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.
Richard A Larson, Ophelia Q P Yin, Andreas Hochhaus, Giuseppe Saglio, Richard E Clark, Hirohisa Nakamae, Neil J Gallagher, Eren Demirhan, Timothy P Hughes, Hagop M Kantarjian,[...]. Eur J Clin Pharmacol 2012
74
12

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Howard A Burris, Herbert I Hurwitz, E Claire Dees, Afshin Dowlati, Kimberly L Blackwell, Bert O'Neil, Paul K Marcom, Matthew J Ellis, Beth Overmoyer, Suzanne F Jones,[...]. J Clin Oncol 2005
487
9

A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum.
Robert A Parise, Merrill J Egorin, Susan M Christner, Dhvani D Shah, Wei Zhou, Jan H Beumer. J Chromatogr B Analyt Technol Biomed Life Sci 2009
21
42

Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS.
Olivia Roth, Odile Spreux-Varoquaux, Stephane Bouchet, Philippe Rousselot, Sylvie Castaigne, Sophie Rigaudeau, Victoria Raggueneau, Patrice Therond, Philippe Devillier, Mathieu Molimard,[...]. Clin Chim Acta 2010
42
21

A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.
Marie-Christine Etienne-Grimaldi, Nicole Renée, Hassan Izzedine, Gérard Milano. J Chromatogr B Analyt Technol Biomed Life Sci 2009
30
30


Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice.
B Blanchet, B Billemont, J Cramard, A S Benichou, S Chhun, L Harcouet, S Ropert, A Dauphin, F Goldwasser, M Tod. J Pharm Biomed Anal 2009
84
10

Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection.
N Widmer, A Béguin, B Rochat, T Buclin, T Kovacsovics, M A Duchosal, S Leyvraz, A Rosselet, J Biollaz, L A Decosterd. J Chromatogr B Analyt Technol Biomed Life Sci 2004
46
17

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Dirk B Mendel, A Douglas Laird, Xiaohua Xin, Sharianne G Louie, James G Christensen, Guangmin Li, Randall E Schreck, Tinya J Abrams, Theresa J Ngai, Leslie B Lee,[...]. Clin Cancer Res 2003
8

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Scott M Wilhelm, Christopher Carter, Liya Tang, Dean Wilkie, Angela McNabola, Hong Rong, Charles Chen, Xiaomei Zhang, Patrick Vincent, Mark McHugh,[...]. Cancer Res 2004
8

Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography.
Andrea Davies, Alison K Hayes, Katy Knight, Sarah J Watmough, Munir Pirmohamed, Richard E Clark. Leuk Res 2010
38
21

Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Karine Titier, Stéphane Picard, Dominique Ducint, Emmanuelle Teilhet, Nicholas Moore, Patrice Berthaud, François-Xavier Mahon, Mathieu Molimard. Ther Drug Monit 2005
69
11

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.
François Guilhot, Timothy P Hughes, Jorge Cortes, Brian J Druker, Michele Baccarani, Insa Gathmann, Michael Hayes, Camille Granvil, Yanfeng Wang. Haematologica 2012
77
10


Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.
Benoit Blanchet, Carole Saboureau, Anne Sophie Benichou, Bertrand Billemont, Fabrice Taieb, Stanislas Ropert, Alain Dauphin, François Goldwasser, Michel Tod. Clin Chim Acta 2009
39
20

Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.
Lokesh Jain, Erin R Gardner, Jürgen Venitz, William Dahut, William D Figg. J Pharm Biomed Anal 2008
44
18

Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.
Amina Haouala, Nicolas Widmer, Monia Guidi, Michael Montemurro, Serge Leyvraz, Thierry Buclin, Chin B Eap, Laurent A Decosterd, Chantal Csajka. Br J Clin Pharmacol 2013
28
28

Therapeutic drug monitoring in cancer--are we missing a trick?
Christophe Bardin, Gareth Veal, Angelo Paci, Etienne Chatelut, Alain Astier, Dominique Levêque, Nicolas Widmer, Jos Beijnen. Eur J Cancer 2014
63
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.